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Incidental reduction in the size of liver hemangioma following use
of VEGF inhibitor bevacizumabq
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Cleveland, OH 44195, USA
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3The Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USABackground/Aims:Hepatic cavernous hemangioma is the second most common liver tumor after metastases. Vascular
endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. High VEGF expression
leads to increased angiogenic activity in cavernous hemangioma endothelial cells. The use of speciﬁc antibodies directed
against VEGF abolishes this vascular endothelial growth-promoting activity in vitro. Bevacizumab is a recombinant
humanized monoclonal antibody directed against VEGF which is used for the treatment of metastatic colorectal cancer
in combination with 5-ﬂuorouracil-based regimens.
Methods:We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological
examination, who showed a signiﬁcant decrease in the size of his liver lesions after bevacizumab treatment. Histology
of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma
endothelial cells. To date, surgical resection provides the only consistently eﬀective method for treatment of hepatic
hemangioma.
Conclusions:This is the ﬁrst documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a
possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bev-
acizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Hepatic cavernous hemangioma accounts for 73% of
all benign liver tumors [1] and is the secondmost common
tumor seen in the liver aftermetastases [2]. Vascular endo-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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regulator of normal and abnormal blood vessel growth
[3]. It is postulated that higher expression of VEGF and
angiopoietins leads to increased angiogenic activity in
cavernous hemangioma endothelial cells (CHECs) [1].
The use of speciﬁc antibodies directed against VEGF
abolishes the vascular endothelial growth-promoting
activity in vitro [4]. Bevacizumab is a recombinant
humanized monoclonal antibody (93% human and 7%
murine) directed against VEGF which is used for the
treatment of metastatic colorectal cancer in combination
with 5-ﬂuorouracil (5-FU)-based regimen [3].
We report a patient with colorectal carcinoma and
suspected liver metastasis on radiological examination
who showed a signiﬁcant decrease in the size of his liverPublished by Elsevier B.V. All rights reserved.
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tomy. Histological examination of the liver lesions
revealed hemangioma; no metastatic colonic adenocar-
cinoma was identiﬁed. This is the ﬁrst documented case
of hepatic hemangioma responsive to antiangiogenic
therapy, suggesting a possible use for these agents in
treating symptomatic patients without surgery.Fig. 2. Histology of the sigmoid colon mass reveals a moderately
diﬀerentiated invasive adenocarcinoma. (H&E 20).2. Case report
A 51-year-old male patient presented to the outpa-
tient surgery department with a bloody bowel move-
ment. He had undergone colonoscopy at another
institution which revealed a tubulovillous adenoma in
the right colon and a near obstructing lesion in the sig-
moid colon. Repeat colonoscopy conﬁrmed a large
ulcerating mass in the sigmoid colon, but the right colo-
nic lesion could not be visualized as the scope was
unable to pass through the sigmoid colon mass. Biopsy
of the sigmoid mass revealed invasive moderately diﬀer-
entiated adenocarcinoma. A staging multiphasic helical
CT scan was performed, revealing a 3.6  2.8 cm lesion
in segment VI of the liver (Fig. 1), suspicious for metas-
tasis. The enhancement characteristics of this lesion
were not consistent with hemangioma. There was also
an 8 mm hypodense lesion in segment V and a similar
8 mm lesion at the junction of segments II and IVa.
The family history was signiﬁcant for the mother being
diagnosed with colon cancer at 74 years of age.
A staged approach for the management of the patient
was planned, including colectomy followed by chemo-
therapy and subsequent liver resection after reassess-
ment of the liver tumors. The patient underwent right
hemicolectomy with ileocolic anastomosis, sigmoid
colectomy with colorectal anastomosis and loop ileos-Fig. 1. CT Scan showing pre-treatment dominant lesion (3.6  2.8 cm)
within segment VI of the liver, suspicious for metastasis (dotted line and
arrow).tomy. The right colonic lesion was diagnosed as a villous
adenoma. The sigmoid colon mass was a moderately dif-
ferentiated invasive adenocarcinoma (Fig. 2). Twenty-
nine lymph nodes were isolated and were negative for
tumor metastasis. The primary tumor was staged as
pT1N0M1. The patient then received four rounds of
FOLFOX chemotherapy (a regimen of oxaliplatin, 5-
ﬂuorouracil and leucovorin) and bevacizumab. Repeat
CT scan showed an interval decrease in size of the right
posterior hepatic lesion. The previously noted lesion was
smaller and less well deﬁned than the prior study. Its
borders were not well deﬁned; however, it was estimated
at approximately 2.5  2.5 cm (Fig. 3). Other previously
seen lesions were not identiﬁed.
At the time of the hepatic resection, the patient
underwent an intraoperative ultrasound which revealed
a single lesion approximately 2–3 cm in diameter in seg-
ment VI of the liver along with an additional smallerFig. 3. Post-bevacizumab CT scan showing a reduction in the size of the
dominant lesion with blurring of borders (dotted line and arrow).
Fig. 4. Histology of the liver lesions reveal hemangioma with strong and
diﬀuse staining for VEGF (inset) and VEGFr2 (H&E 20, H&E 40).
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ments VI and IV was performed. Microscopic examina-
tion of both lesions revealed benign cavernous
hemangioma. Both lesions showed prominent ﬁbrous
stroma as well as benign and variably dilated vascular
spaces (Fig. 4). Cytologic atypia was not identiﬁed. Met-
astatic adenocarcinoma was not identiﬁed. Immunohis-
tochemical staining for VEGF (Chemicon International,
Inc., Temecula, CA) revealed strong, diﬀuse staining in
the hepatic hemangioma endothelial cells, while the liver
sinusoidal endothelial cells were negative (Fig. 4 inset).
Immunostaining for anti-VEGFr2 (Cell Signaling, Inc.,
Danvers, MA) also revealed a strong, diﬀuse staining
in the hepatic hemangioma endothelial cells while the
liver sinusoidal endothelial cells also showed some pos-
itivity (Fig. 4, inset).3. Discussion
Hepatic hemangioma is the commonest benign tumor
in the liver, with a frequency of up to 7.3% and varying
in size from a few millimeters to nearly replacing the
liver in diﬀuse haemangiomatosis [5,6]. Hepatic heman-
giomas are usually asymptomatic, incidental lesions [1].
Common symptoms in infancy include hepatomegaly
and congestive heart failure [7]. In adults, hepatic
hemangiomas may be associated with right upper quad-
rant pain or discomfort, nonspeciﬁc symptoms, or jaun-
dice [6]. Although rare, the most severe presentation is a
ruptured hemangioma with hemorrhagic shock [1].
The pathogenesis of cavernous hemangioma remains
unclear, but two hypotheses have been proposed. One
proposes that these tumors result from abnormal angio-
genesis, with an increase of pro-angiogenic factors like
VEGF and matrix metalloproteinases (MMP) and
downregulation of angiogenesis inhibitors [8,9]. Others
suggest genetic defects may be involved [10].In the early 1970s, Folkman et al. [11] identiﬁed a
tumor-angiogenesis factor that was mitogenic to
tumor capillary endothelial cells and suggested that
blocking this factor might arrest tumor growth.
VEGF is now recognized as an essential regulator of
normal and abnormal blood vessel growth [3]. VEGFs
are encoded by a family of genes including VEGF-A,
-B, -C, -D, and placental growth factor (PGF) [12].
VEGF- A, -B, and PGF are predominantly required
for blood vessel formation, while VEGF-C and -D
are essential for the formation of lymphatic vessels
[3]. The biological functions of VEGF are mediated
through binding to VEGFR-1 (Flt-1), VEGFR-2
(KDR/Flk-1), and VEGFR-3 (Flt-4) receptors [13].
VEGFR-2 is the predominant receptor in angiogenic
signaling and acts via the PI 3-kinase/Akt pathway
and the classical Ras-dependent signaling cascade
impinging on MAP kinases such as ERK1 and
ERK2 [3]. Zhang et al. found that the expression of
VEGF-A was increased in all kinds of hepatic CHECs
when compared to human liver sinusoidal endothelial
cells (LSECs), indicating that the increased angiogenic
activity in CHECs might be related to a higher expres-
sion of VEGF [1].
Stromal cells cultured from surgically removed life-
threatening hemangiomas released an endothelial cell
mitogen in vitro that was indistinguishable from VEGF,
and systemic injections of neutralizing anti-VEGF anti-
bodies inhibited the angiogenic response in nude mice
grafted with neonatal hemangioma cells [4] VEGF
blockade in tumors has been shown to have a direct
and rapid antivascular eﬀect through deprivation of
tumor vascular supply and inhibition of endothelial pro-
liferation [3]. Isner et al. observed that transduction of a
plasmid coding for VEGF in human ischemic arteries
led to the formation of cutaneous hemangioma that
regressed when VEGF bioavailability decreased, con-
ﬁrming the pathophysiological role of VEGF in this dis-
ease [14].
To date, whenever treatment for hepatic hemangioma
is indicated, surgical resection provides the only consis-
tently eﬀective method reported but may not be feasible
in patients with in patients with multiple hemangiomas,
extensive hilar involvement or multiple comorbidities
[15]. Embolization, hepatic artery ligation, radiation
therapy and corticosteroids have been tried in these
patients but have limited success and are often associ-
ated with signiﬁcant morbidity [6]. Drugs that interfere
with VEGF signaling might open up a new ﬁeld in hem-
angioma treatment. Bevacizumab is a recombinant
humanized monoclonal antibody directed against
VEGF and approved for treatment of metastatic colo-
rectal cancer in combination with a 5-ﬂuorouracil-based
regimen. Studies of bevacizumab alone or in combina-
tion with chemotherapy reported encouraging eﬃcacy
and safety results in hepatocellular, ovarian, renal cell,
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tissue sarcoma [3].
Mitchell et al. [16] reported bevacizumab to induce a
strong biological and clinical response in a patient of
symptomatic hereditary hemorrhagic telangiectasia with
liver involvement complicated by high-output cardiac
failure, portal hypertension and cholestasis. There was
a marked diminution of hepatic vascularity, a twofold
reduction in liver volume and normalization of cardiac
output, thus alleviating the need for a liver transplanta-
tion. Therapy was well tolerated. The authors suggested
that biological agents targeting angiogenic growth fac-
tors represent a novel form of therapy for these patients
[16]. A combination of intravitreal bevacizumab with
photodynamic therapy has been reported to successfully
treat a case of juxtapapillary retinal capillary hemangi-
oma (RCH) [17]. Intravitreal bevacizumab has also been
shown to be therapeutic in patients with vasoprolifera-
tive retinal tumor [18] and show partial therapeutic
response when used systematically to treat juxtapapil-
lary RCH [19]. However, further studies are yet needed
to assess the eﬃcacy of bevacizumab in vasoproliferative
tumors.
In our case, the incidental use of bevacizumab led to a
decrease in the size of the dominant lesion and com-
pletely treated the other smaller lesions visualized on
the initial CT scan. The fact that these lesions were actu-
ally hemangiomas and that VEGF plays a central role in
pathogenesis of hemangioma suggests that bevacizumab
(an anti-VEGF antibody) caused regression of hemangi-
oma in our patient. We believe that this serendipitous
concurrence holds promise in the use of bevacizumab
for treatment of not only hepatic hemangiomas but
hemangiomas in other parts of the body as well.
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